P-132 Malignant transformation of choledochal cysts: Description of a North African series of 7 cases

Abstract

The patients in the combined-therapy group were associated with older age (p ¼ 0.033) and larger tumor size (p¼0.042) compared with patients in the sorafenib-only group. After 1:2 PSM, 25 patients in the combined-therapy group were well matched with 50 patients in the sorafenib-only group. The combined-therapy group showed significantly improved overall response rate (ORR) and disease control rate (DCR) compared with the sorafenib-only group (24.0% vs 4.0%, p¼0.025; 48.0% vs 24.0%, p¼0.036). The median PFS was significantly longer in the combined-therapy group than the sorafenib-only group (7.1 months vs 6.0 months, p¼0.040), while the median OS was similar in the two groups (7.4 vs 7.0 months, p¼0.513). No difference was noted in the rate of adverse reactions between the combined-therapy group and the sorafenib-only group (32.0% vs 22.0%, p¼0.348), and the symptoms were relieved after treatment. Conclusion:The combination treatment of camrelizumab with sorafenib showed promising efficacy with acceptable safety for the management of advanced HCC, but further studies with larger sample sizes and longer follow-up duration or randomized trials are needed to identify the potential therapeutic value.Legal entity responsible for the study: The authors.